David C. Turner

7.3k total citations · 1 hit paper
123 papers, 5.5k citations indexed

About

David C. Turner is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, David C. Turner has authored 123 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 36 papers in Oncology and 23 papers in Cell Biology. Recurrent topics in David C. Turner's work include Cell Adhesion Molecules Research (20 papers), CAR-T cell therapy research (15 papers) and Lipid Membrane Structure and Behavior (15 papers). David C. Turner is often cited by papers focused on Cell Adhesion Molecules Research (20 papers), CAR-T cell therapy research (15 papers) and Lipid Membrane Structure and Behavior (15 papers). David C. Turner collaborates with scholars based in United States, Switzerland and Canada. David C. Turner's co-authors include Hans M. Eppenberger, Sol M. Grüner, Ludwig Brand, Theo Wallimann, Matthias Chiquet, Thressa C. Stadtman, Mark W. Täte, Peter T. C. So, Shyamsunder Erramilli and Kurt R. Gehlsen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

David C. Turner

121 papers receiving 5.2k citations

Hit Papers

Quantitative estimation o... 1968 2026 1987 2006 1968 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Quantitative estimation of protein binding site polarity. Fluorescence of N-arylaminonaphthalenesulfonates
    1968 373 citations David C. Turner et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David C. Turner 3.0k 1.1k 868 616 490 123 5.5k
R.F.A. Zwaal 6.9k 2.3× 1.1k 1.0× 476 0.5× 460 0.7× 330 0.7× 135 14.4k
Philip J. Hogg 4.0k 1.3× 1.3k 1.2× 516 0.6× 613 1.0× 403 0.8× 186 8.4k
Kevin H. Mayo 6.0k 2.0× 656 0.6× 570 0.7× 1.7k 2.7× 519 1.1× 283 10.5k
Frauke Alves 2.5k 0.8× 716 0.6× 1.1k 1.3× 1.2k 1.9× 180 0.4× 169 5.7k
Stephen J. Kennel 3.4k 1.1× 903 0.8× 1.2k 1.4× 857 1.4× 326 0.7× 203 6.8k
E.D. Lowe 2.8k 0.9× 847 0.8× 402 0.5× 563 0.9× 222 0.5× 66 4.2k
Sharon L. Campbell 6.4k 2.1× 2.2k 2.0× 652 0.8× 1.6k 2.5× 269 0.5× 149 9.0k
Paul Comfurius 4.3k 1.4× 674 0.6× 386 0.4× 298 0.5× 191 0.4× 79 9.4k
Ben N. G. Giepmans 6.2k 2.1× 1.2k 1.0× 178 0.2× 461 0.7× 491 1.0× 105 9.8k
Mattias Belting 5.6k 1.9× 1.1k 1.0× 450 0.5× 489 0.8× 266 0.5× 124 7.8k

Countries citing papers authored by David C. Turner

Since Specialization
Citations

This map shows the geographic impact of David C. Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Turner more than expected).

Fields of papers citing papers by David C. Turner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Turner. The network helps show where David C. Turner may publish in the future.

Co-authorship network of co-authors of David C. Turner

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Turner. A scholar is included among the top collaborators of David C. Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Turner. David C. Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jamois, Candice, David C. Turner, Leonid Gibiansky, et al.. (2025). Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL. Clinical Pharmacology & Therapeutics. 118(4). 917–927. 1 indexed citations
2.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations
3.
Li, Chi‐Chung, Chi‐Chung Li, Brendan C. Bender, et al.. (2024). A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma. Clinical Pharmacology & Therapeutics. 117(2). 465–474. 3 indexed citations
4.
Bender, Brendan C., et al.. (2024). Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies. Clinical Cancer Research. 31(2). 245–257. 11 indexed citations
5.
Turner, David C.. (2024). Vapor Phase Electrochemistry 2: Spherical and Spheroidal Air Plasmas. SHILAP Revista de lepidopterología. 38(3). 399–426.
6.
Turner, David C., et al.. (2023). Pharmacokinetics of biologics in gastric cancer. Clinical and Translational Science. 16(4). 564–574. 4 indexed citations
7.
Angevin, Eric, Stefanie L. Groenland, Todd M. Bauer, et al.. (2020). 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Annals of Oncology. 31. S3–S3. 2 indexed citations
8.
9.
10.
Turner, David C., Anna Kondic, Keaven M. Anderson, et al.. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clinical Cancer Research. 24(23). 5841–5849. 156 indexed citations
11.
Garon, Edward B., Martin Reck, Delvys Rodríguez‐Abreu, et al.. (2017). P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1290–S1291. 1 indexed citations
12.
Kieran, Mark W., Susan Chi, Stewart Goldman, et al.. (2015). A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Child s Nervous System. 31(9). 1433–1445. 13 indexed citations
13.
Wright, Karen, Vinay M. Daryani, David C. Turner, et al.. (2015). Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. Neuro-Oncology. 17(12). 1620–1627. 23 indexed citations
14.
Turner, David C., Fariba Navid, Najat C. Daw, et al.. (2014). Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing. Clinical Cancer Research. 20(10). 2783–2792. 40 indexed citations
15.
Vilgelm, Anna E., Jeff S. Pawlikowski, Yan Liu, et al.. (2014). Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells. Cancer Research. 75(1). 181–193. 82 indexed citations
16.
Chaturvedula, Ayyappa, et al.. (2014). Population Pharmacokinetic Pharmacodynamic Modeling of Caffeine Using Visual Analogue Scales. Pharmacology & Pharmacy. 5(4). 444–454. 1 indexed citations
17.
Roberts, Michael S., David C. Turner, Abhijit Ramachandran, et al.. (2013). Determination of crenolanib in human serum and cerebrospinal fluid by liquid chromatography–electrospray ionization-tandem mass spectrometry (LC–ESI-MS/MS). Journal of Chromatography B. 929. 1–5. 4 indexed citations
18.
Liu, David, Andrew S. Kennedy, David C. Turner, et al.. (2009). Minimally Invasive Techniques in Management of Hepatic Neuroendocrine Metastatic Disease. American Journal of Clinical Oncology. 32(2). 200–215. 18 indexed citations
19.
Markowitz, Michael A., David C. Turner, Brett D. Martin, & Bruce P. Gaber. (1997). Diffusion and transfer of antibody proteins from a sugar-based hydrogel. Applied Biochemistry and Biotechnology. 68(1-2). 57–68. 11 indexed citations
20.
Lewis, Ruthven N. A. H., et al.. (1990). Thermotropic characterization of the 2-O-acyl,polyprenyl α-d-glucopyranoside isolated from palmitate-enriched Acholeplasma laidlawii B membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1026(1). 21–28. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R.F.A. Zwaal Breakdown of academic impact, for papers by Philip J. Hogg Breakdown of academic impact, for papers by Kevin H. Mayo Breakdown of academic impact, for papers by Frauke Alves Breakdown of academic impact, for papers by Stephen J. Kennel Breakdown of academic impact, for papers by E.D. Lowe Breakdown of academic impact, for papers by Sharon L. Campbell Breakdown of academic impact, for papers by Paul Comfurius Breakdown of academic impact, for papers by Ben N. G. Giepmans Breakdown of academic impact, for papers by Mattias Belting
Rankless by CCL
2026